For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Tafamidis and Tafamidis meglumine represents a genuine change. These groundbreaking therapies preserve the transthyretin protein, halting its destructive build-up and reducing website the impact of the condition . Patients are now ex